Codexis to Participate in Piper Sandler 38th Annual Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Codexis (CDXS) will participate in the Piper Sandler 38th Annual Healthcare Conference, scheduled for December 1–3, 2026, in New York City. Management will join a fireside chat on December 2 at 3:00 p.m. ET.
A live webcast will be available on the company’s investor relations website, with a replay available for 90 days after the event.
Key Terms
oligonucleotide medical
rnai medical
sirna medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Piper Sandler 38th Annual Healthcare Conference, being held December 1-3, 2026, in New York, New York.
Management will participate in a fireside chat on Wednesday, December 2, 2026, at 3:00 pm ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website at https://ir.codexis.com. A replay will be archived for 90 days following the event.
About Codexis
Codexis® is a leading provider of high-performance enzymatic solutions for efficient and scalable therapeutics manufacturing. The company is currently developing its proprietary ECO Synthesis® Manufacturing Platform, an aqueous enzymatic process that may offer a scalable alternative to traditional solid phase organic synthesis of oligonucleotide manufacturing. Initially, Codexis is applying its technology to address the rapidly growing demand for RNAi therapeutics. Codexis’ unique enzymes can drive improvements such as higher yields, increased purity, reduced energy usage and waste generation, stereoisomer control of siRNA, and improved overall capacity in manufacturing at substantially lower capital requirements, all of which may lead to greater efficiency and reduced costs. In addition, the company supplies high-performance enzymes through its BioCatalysis business that are used in the manufacture of multiple commercially available small molecule therapeutics. For additional information, please visit https://www.codexis.com.
For More Information
Investor Contact
Georgia Erbez
(650) 421-8100
ir@codexis.com